Comparison of Follitropin Delta and Follitropin Alfa in Combination With Menotropin

NCT07457684 | Completed

• 1 other identifier: BONANZA
• Study Type: observational
• Target: 846
• Locations: 1 country
• Sites: 1

Brief Summary

The goal of this retrospective study is to compare the effectiveness and cost-effectiveness of two mixed ovarian stimulation protocols in women undergoing in vitro fertilization (IVF). The main questions it aims to answer are:

• Does the combination of follitropin delta + HP-hMG result in a higher number of utilizable blastocysts per treatment cycle compared to follitropin alfa + HP-hMG?
• Does the follitropin delta based mixed protocol reduce total gonadotropin dose and cost per usable blastocyst while maintaining or improving pregnancy outcomes? Researchers will compare follitropin alfa (Gonal-F®) + HP-hMG (Menopur®) with follitropin delta (Rekovelle®) + HP-hMG (Menopur®) to determine which protocol improves ovarian response, embryology outcomes, pregnancy rates, and overall treatment cost-efficiency.

Conditions

IVF Outcomes; OVARIAN STIMULATION

Keywords

follitropin delta; follitropin alfa; menotropins; IVF

Outcome Measures

Primary Outcomes (1)

• Number of utilizable blastocysts per treatment cycle

  For IVF performed from January 2018 to December 2024

Secondary Outcomes (9)

• Number of stimulation days

  For IVF performed from January 2018 to December 2024

• Totals doses of rFSH, HP-hMG, and FSH

  For IVF performed from January 2018 to December 2024

• Costs of rFSH, HP-hMG, and FSH

  For IVF performed from January 2018 to December 2024

• Number of retrieved oocytes

  For IVF performed from January 2018 to December 2024

• Number of mature oocytes (MII)

  For IVF performed from January 2018 to December 2024

Study Arms (2)

Follitropin alfa (Gonal-F®) + HP-hMG (Menopur®)

Follitropin delta (Rekovelle®) + HP-hMG (Menopur®)

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: female
• Healthy Volunteers: No
• Age Groups: Adult (18-64)
• Sampling Method: Probability Sample

Study Population

Women who underwent their first IVF cycle between 2018 and 2024 at the ovo clinic

You may qualify if:

• Women between 18-45 years included
• First ovarian stimulation cycle only
• Patients who used mixed protocols combining menotropin and follitropin alfa or delta
• Patients whose Rekovelle doses were prescribed using the algorithm based on AMH and weight.

You may not qualify if:

• Patients who did not follow the algorithm to determine follitropin delta dosing and who required dose adjustments during the stimulation
• Patients who took concomitant treatment, such as corticosteroids, low molecular weight heparin, nonsteroidal anti-inflammatory drugs, recombinant LH or intra-vaginal vasodilators
• Oocytes donation or fertility preservation cycles

Sponsors & Collaborators

• Clinique Ovo: lead

Study Sites (1)

Clinique ovo

Montreal, Quebec, H4P 2S4, Canada

Location

Study Officials

• Isaac-Jacques Kadoch, MD

  Clinique Ovo

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 24, 2026
• First Posted: March 9, 2026
• Study Start: December 5, 2025
• Primary Completion: December 15, 2025
• Study Completion: December 15, 2025
• Last Updated: March 9, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)